It is often considered that the UK grants access to new medicines upon marketing authorisation (MA) approval, while patients in countries such as France or Belgium gain access only after significant delays. The objective is to quantify differences in time to market access between the UK (excluding Scotland), France and Belgium and to identify contributing factors.